Diagnostics
3 Early-Stage Cancer Diagnostics Startups to Watch in 2026
DealBio tracks early-stage cancer diagnostics startups across Europe and North America. These 3 startups are building around treatment selection, biomarker discovery and more accessible screening.
- Cancer Diagnostics
- Biomarkers
- Cancer Screening
- Precision Medicine
DealBio tracks early-stage cancer diagnostics startups across Europe and North America. These 3 startups are building around treatment selection, biomarker discovery and more accessible screening.
Cancer diagnostics is moving toward more specific clinical questions: who is likely to respond to treatment, which biological signals can reveal disease earlier, and how screening can become easier to complete.
The investment opportunity is strongest where a promising signal can become a reproducible test with a clear user and next action. That puts clinical validation, sample handling and route to use at the center of the commercial story.
At a Glance
- EVIIVESwitzerland2022Immunotherapy response
- CancerTwinSweden2026Early cancer biomarkers
- Papilio BioFrance2024At-home HPV screening
01
EVIIVE
Developing blood tests that predict which cancer patients respond to immunotherapy.
- Country
Switzerland- Founded
- 2022
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why EVIIVE stands out
EVIIVE combines human melanoma evidence with a defined treatment-selection use case. Research from the founding team linked extracellular-vesicle signals to immune-checkpoint response, while the startup has secured CHF 300,000 in non-dilutive funding and a companion-diagnostic partnership with Ymmunobio.
The University of Zurich spinout retains close clinical links to University Hospital Zurich, connecting the blood-test platform to immuno-oncology expertise and patient samples.
What EVIIVE is building
EVIIVE profiles individual extracellular vesicles in blood to identify signals associated with immunotherapy response. Its IMPASS platform focuses on single-vesicle profiling, while IMPACT adds molecular analysis around the most informative signals.
The first use case is advanced melanoma, where the goal is to identify likely responders before treatment begins and support more precise use of immune-checkpoint therapy.
Using digital tumor models to discover early cancer biomarkers.
- Country
Sweden- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
- Mikael Benson
Why CancerTwin stands out
CancerTwin is commercializing research from Karolinska Institutet and the Swedish Digital Twin Consortium. Its scientific foundation includes a 2025 prostate-cancer biomarker study involving nearly 2,000 patients and broader work on medical digital twins for personalized medicine.
Scientific adviser Joseph Loscalzo adds systems-biology expertise from Harvard Medical School, strengthening the link between complex disease modeling and clinically useful biomarker development.
What CancerTwin is building
CancerTwin builds computational tumor models by combining routine clinical information with multi-omics and spatial single-cell data. The models are designed to prioritize biological mechanisms and biomarkers associated with early disease.
The commercial path is to turn those prioritized signals into practical diagnostic markers that can be tested in routine samples and validated for defined cancer indications.
Developing a rapid at-home HPV test with results in 15 minutes.
- Country
France- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why Papilio Bio stands out
Papilio Bio has reached proof of concept for its rapid HPV self-test and filed its first European patent application in 2025. It also won the Health-Biotech category at Paris-Saclay SPRING 2026 and joined Genopole and Agoranov programs.
Co-founder Serena Petracchini brings microbiology and biotechnology research experience from Institut Pasteur, while Chiara Cespi Polisiani adds startup operations and go-to-market experience.
What Papilio Bio is building
Papilio Bio is developing a disposable HPV self-test that combines self-collection, molecular signal amplification and a visible result in about 15 minutes. The test is designed to work without laboratory processing or a separate electronic reader.
An optional companion app is intended to guide sampling, explain results and support follow-up, while the diagnostic result remains visible on the physical test.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
These three startups sit at three different points in the cancer-diagnostics pathway: treatment selection, biomarker discovery and screening access. That matters because each can build defensibility in a different place. Treatment-response diagnostics can accumulate outcome-linked clinical data, biomarker platforms can build proprietary disease models and validation cohorts, and at-home tests can combine assay performance with distribution and repeat use.
The shared opportunity is to own more than the test result. The strongest businesses can become embedded in the decision itself: which patient receives a therapy, which biological signal advances into validation, or whether screening happens at all. That is where a diagnostic platform can turn technical performance into a durable clinical and commercial position.
Methodology
DealBio selected these three early-stage cancer diagnostics startups because each is developing a defined diagnostic product around treatment selection, earlier detection or screening. The group spans liquid biopsy, digital biomarker discovery and molecular self-testing.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.